Welcome to Medivizor!

You're browsing our sample library. Feel free to continue browsing. You can also sign up for free to receive medical information specific to your situation.

Posted by on Jul 14, 2019 in Multiple Myeloma | 0 comments

In a nutshell

This study looked at the safety and effectiveness of carfilzomib (Kyprolis), thalidomide (Thalomid) and dexamethasone (Decadron) in the treatment of patients with multiple myeloma. Researchers concluded that this treatment plan is safe and effective in these patients.

Some background

Multiple myeloma is a cancer of the bone marrow. It is often treated with a stem cell transplant (SCT). Some patients may not be eligible for a SCT at diagnosis. For these patients, other treatments are necessary initially. It is important to research the safety and effectiveness of such drugs.

Methods & findings

111 patients with newly diagnosed multiple myeloma were included in the study. All patients were initially treated with carfilzomib, thalidomide, and dexamethasone (KTd). This induction therapy was meant to kill cancer cells. Patients then received a SCT, followed by a consolidation therapy with KTd. Consolidation therapy is given to kill any remaining cancer cells in the body. Patients were followed up for an average of 58.7 months.

The overall response rate was 93%. 18% of patients had a complete response. After consolidation therapy, the response rate was 94%.

The average survival without cancer progression was 58 months. Overall survival after 5 years was 76%.

Side effects in the blood occurred in 15% of patients. Side effects were also seen related to infection (11%), lungs (8%), skin (9%) and blood vessels (9%).

The bottom line

The study concluded that KTd treatment was safe and effective in patients with multiple myeloma .

The fine print

This study was funded by the industry. Further studies are needed.

Published By :


Date :

Apr 04, 2019

Original Title :

Phase 2 study of carfilzomib, thalidomide, and low-dose dexamethasone as induction and consolidation in newly diagnosed, transplant eligible patients with multiple myeloma, the carthadex trial.

click here to get personalized updates